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ABSTRACT
We investigated whether a novel chemotherapy-alone conditioning regimen would permit durable engraft-
ment of standard doses of CD34 purified stem cell grafts from full-haplotype mismatched related donors. We
also examined the role of infusing limited doses of donor leukocytes for prevention of leukemia relapse. Our
conditioning regimen consisted of thiotepa, fludarabine, rabbit antithymocyte globulin, melphalan, cyclo-
sporin, and prednisolone. Since October 1998, 14 patients with high-risk leukemia were treated; 13 donor-
patient pairs shared 3 of 6 HLA antigens, and 1 pair shared 5 of 6 HLA antigens. A median of 5.4 106 CD34
cells per kilogram, 1.62 104 CD3 cells per kilogram, and 9.32 104 CD19 cells per kilogram were infused.
T-cell depletion was the only graft-versus-host disease (GVHD) prophylaxis. All patients had prompt engraft-
ment, and no late graft rejections were observed. All surviving patients received at least 1 infusion of donor
whole blood containing 5, 7, 10, 25, or 50  103 CD3 cells per kilogram between days 25 and 95 after
transplantation, after which 8 developed acute GVHD (3 grade I, 2 grade II, 2 grade III, and 1 grade IV) and
2 developed a bronchiolitis obliterans–like syndrome. After attaining complete remission, 5 patients relapsed
and died with active leukemia. The estimated relapse-related mortality at 4 years is 38.1%. As of June 15, 2003,
6 of 14 patients have survived a median of 43.5 months after transplantation with 100% donor cells. All 6
surviving patients developed acute GVHD and had a natural killer cell mismatch with their donors in the
direction of graft versus host. The estimated overall survival and event-free survival for the 14 patients at 4
years is 41.7%  13.5%.
© 2003 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Allogeneic stem cell transplantation is curative for
signiﬁcant number of patients with hematologic ma-
ignancies [1]. Although the ideal donor is a genotyp-
cally HLA-matched sibling, most patients in need of
uch a procedure do not have a suitable donor in the
amily. This has led in past decades to a steady incre-
ent in the use of phenotypically HLA-matched vol-
nteer donors from the international registries [2,3].
The odds of ﬁnding a matched unrelated donorange from 60% to 70% for white populations to less o
B&MThan 15% in ethnic minorities [4]. Another potential
lternative donor is a genotypically haploidentical
amily member; such a member is readily available for
ore than 90% of patients. Other advantages in favor
f such a donor are the possibility to select for sex, age,
nd cytomegalovirus (CMV) status and to have con-
inued access to donor cells for further immunologic
nitiatives. This strategy has been used with success in
hildren with severe combined immunodeﬁciency
nd, more recently, in patients with hematologic ma-
ignancies [5-10]. Historical barriers to the successfulconditioning regimen Hematologic m
oi:10.1016/S1083-8791(03)00263-5nciesutcome of these patients have been severe graft-
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versus-host disease (GVHD) in non–T cell–depleted
grafts, delayed immune reconstitution, and graft re-
jection and disease relapse in T cell–depleted grafts.
With the recent availability of automated devices for
CD34 cell selection, it has become possible to T-cell
deplete with a fairly simple technology. This has al-
lowed the infusion of a dose of T cells below the
threshold for acute GVHD in the haploidentical set-
ting. The risk of graft rejection has been decreased by
the use of highly immunosuppressive total body irra-
diation–including conditioning regimens, as well as by
the infusion of megadoses of donor CD34 cells
[7,8,10,11].
This study was designed to offer a potentially
curative transplantation for patients with high-risk
leukemia who lacked a suitable donor in the family
and in the international registries. To develop a pro-
cess that is more widely applicable worldwide, we have
developed a non–TBI-containing preparative regimen
for haploidentical transplantation [12]. We also inves-
tigated whether standard doses of puriﬁed CD34
cells would induce durable donor engraftment in this
setting. Finally, we wanted to examine whether the
infusion of a controlled number of donor leukocytes
after transplantation would decrease leukemia relapse.
METHODS
Patients
Between October 1998 and August 2002, 14 pa-
tients with poor-prognosis acute myeloid leukemia
(AML) or chronic myeloid leukemia (Table 1) were
treated at our center with an allogeneic stem cell
transplant from a family donor sharing only 1 haplo-
type with the patient. These patients did not have a
related or unrelated donor available. Written, in-
formed consent was obtained both from the patients
and the donors.
HLA Typing and Donors
Patients and potential donors were studied by sin-
gle-strand polymorphism DNA polymerase chain re-
action for HLA class I and II alleles. Mixed lympho-
cyte cultures were not performed. Of the 14 patient-
donor pairs, 13 were a full 1-haplotype mismatch, and
1 patient shared 5 of 6 HLA antigens with his donor.
The donors were the father in 7 cases, the mother in
1 case, a sibling in 3 cases, and a son or daughter in 3
cases. None of the patients or donors was homozygous
for HLA-A, -B, and -DR; therefore, all patient-donor
pairs were mismatched both in the direction of graft
versus host and of host versus graft. The donors were
not selected according to potential natural killer (NK)
cell alloreactivity against the host; the degree of mis-
match between donor killer immunoglobulin-like re-
ceptors (KIRs) and host HLA class I alleles (HLA-A,
-Bw4, and -C) was ascertained only at the time of
evaluation of disease relapse and survival.
Stem Cell Mobilization, Collection, and Processing
Peripheral blood stem cells were mobilized with
granulocyte colony-stimulating factor (G-CSF) 10 to
12 g/kg/d subcutaneously, divided into 2 administra-
tions, for 5 days. Standard-volume leukaphereses, pro-
cessing 2 total blood volumes, were performed via
peripheral vein by using a CS3000 Plus continuous
ﬂow cell separator (Baxter, Deerﬁeld, IL) on days 4
and 5 of G-CSF administration. Each leukapheresis
was immediately processed, and the CD34 cell selec-
tion was performed with the automated CliniMacs
device (Miltenyi Biotec, Bergisch-Gladbach, Ger-
Table 1. Patient Characteristics
Unique
Patient Number
Age (y)/
Sex Disease Status
Prior
Autologous
Transplantation
Time from
Diagnosis to
Haploidentical
Transplantation (mo)
Al 164 35/M Primary resistant AML No 9
Al 167 22/M AML third CR Yes 33
Al 170 13/M Resistant secondary AML No 7
Al 172 18/F Resistant secondary AML No 4
Al 176 18/F Acute byphenotypic leukemia first CR No 12
Al 181 45/M Resistant relapsed AML Yes 47
Al 187 42/F AML third CR Yes 44
Al 193 27/M AML third CR Yes 48
Al 197 37/M CML second blastic phase No 44
Al 200 21/F CML accelerated phase No 12
Al 206 22/M Primary resistant AML No 8
Al 222 23/F Primary resistant AML No 3
Al 236 44/F Resistant relapsed AML No 13
Al 242 40/M AML second CR No 17
M indicates male; F, female; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CR, complete remission.
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many). Thereafter, the CD34 population was ana-
lyzed and cryopreserved. For the CD34 cell selection,
the instructions of the manufacturer were followed
with the exception of the addition of 250 mg of im-
munoglobulin (Octapharma, Wien, Austria) before
the addition of the anti-CD34 monoclonal antibody
to prevent nonspeciﬁc binding of B cells to the
antibody. Because of a low CD34 cell count after the
ﬁrst mobilization, 1 donor had a third leukapheresis
after a second stimulation with G-CSF. Our aim was
to collect at least 5  106 donor CD34 cells per
kilogram of the recipient’s body weight. On the day
of transplantation, the CD34 cells were gently
thawed and immediately administered to the patient
without further ﬂuorescence-activated cell sorter
(FACS) analysis.
Conditioning Regimen
Our conditioning regimen consisted of thiotepa 5
mg/kg/d on day 9 and day 8, ﬂudarabine 40 mg/
m2/d on day 9 to day 5, rabbit antithymocyte
globulin (ATG; Thymoglobulin; IMTIX Pasteur
Me´rieux Connaught, Paris, France) 5 mg/kg/d on day
7 to day 3 as a 12- to 24-hour infusion, melphalan
60 mg/m2/d on day 4 and day 3, cyclosporin 3
mg/kg/d on day 10 to day 2, and prednisolone 2
mg/kg/d on day 7 to day 3 (1 mg/kg before the
administration of ATG and 1 mg/kg with ATG). A
schema of the conditioning regimen is depicted in
Figure 1.
Infection Prophylaxis, Growth Factor
Administration, and Prevention of Hepatic
Veno-Occlusive Disease
All patients were isolated in high-efﬁciency par-
ticulate air–ﬁltered positive-pressure air-ﬂow rooms
from day9 until the third day of neutrophils1000/
L. They all received ciproﬂoxacin 500 mg orally
twice daily from day 10 to the initiation of broad-
spectrum intravenous antibiotics due to neutropenic
fever, itraconazole 200 mg orally twice daily from day
10 until the eventual institution of liposomal am-
photericin B or until discharge, acyclovir 500 mg/m2
every 8 hours intravenously from day 10 and
switched to 800 mg orally every 12 hours after day 21
to day 30, and trimethoprim sulfamethoxazole 960 mg
orally twice daily from day 10 to day 4. After
discharge, all patients continued to receive, at least
until 18 months after transplantation, amoxicillin 500
mg orally twice daily, acyclovir 200 mg orally twice
daily, itraconazole 200 mg orally twice daily, and tri-
methoprim sulfamethoxazole 960 mg orally twice
daily 3 days per week. Despite the positivity for CMV
immunoglobulin G in 13 of 14 patients, no speciﬁc
prophylaxis with ganciclovir or foscarnet was per-
formed. All patients received irradiated, leukocyte-
depleted blood products, which were not analyzed for
CMV status. All patients received intravenous immu-
noglobulin (Octapharma) 500 mg/kg weekly from day
10 until 3 months after transplantation, after which
it was administered twice per month until day 180 and
then once per month until 1 year after transplantation.
All patients received G-CSF 10 g/kg/d intrave-
nously from day 1 until consistent neutrophil engraft-
ment. All patients also received prostaglandin E1 0.5
mg/d by continuous infusion as prophylaxis for he-
patic veno-occlusive disease. This is a standard proce-
dure at our center for patients receiving myeloablative
conditioning regimens.
Assessment of Engraftment and Immunologic
Studies
Engraftment was documented conventionally.
Chimerism analysis of unseparated peripheral blood
leukocytes was assessed monthly until day 180 and
every 2 to 3 months thereafter by polymerase chain
reaction ampliﬁcation of hypervariable tandem repeat
regions with different DNA polymorphisms, as de-
scribed elsewhere [13].
With the frequency described for the chimerism
studies, peripheral blood lymphocytes were also stud-
ied by ﬂow cytometry (Scalibur FACS Scan; Becton
Dickinson, Franklin Lakes, NJ) for a number of T-
cell, B-cell, and NK-cell antigens, including CD2,
CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD56,
CD25, CD69, HLA-DR, T-cell receptor (TCR) /,
TCR /	, CD45RO, and CD45RA, all purchased
from Becton Dickinson, by following a methodology
previously published [14].
Administration of Donor Leukocytes after
Transplantation and GVHD
All patients received at least 1 infusion of donor
whole blood between day 25 and day 95 after trans-
plantation with the intent of hastening immune recov-
Figure 1. Schema of the conditioning regimen. Thio. indicates
thiotepa; Mel., melphalan. The doses of each drug are speciﬁed in
Methods. The arrow indicates the infusion of the graft. The abscissa
represents the days before transplantation.
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ery and decreasing the risk of relapse (Table 2). Five
patients received 5  103 donor CD3 cells per kilo-
gram, 1 patient received 7  103 donor CD3 cells
per kilogram, 3 patients received 1  104 donor
CD3 cells per kilogram, 2 patients received 2.5 
104 donor CD3 cells per kilogram, and 3 patients
received 5  104 donor CD3 cells per kilogram.
After the ﬁrst administration, 1 patient who received
2.5  104 donor CD3 cells per kilogram on day 58
was infused with 4.5  104 donor CD3 cells per
kilogram on day 72 because of persistent pancytopenia
not responsive to growth factor administration, and
another patient who received 7  103 donor CD3
cells per kilogram on day 31 received a second admin-
istration of 2 104 donor CD3 cells per kilogram on
day 83. Other patients received higher doses of donor
leukocytes because of leukemia relapse (discussed in
more detail in Results). The diagnosis and degree of
acute and chronic GVHD were assessed according to
established criteria published in detail elsewhere
[15,16].
Assessment of Survival and Statistical Analysis
All patient details were routinely introduced and
analyzed with the StemSoft software database (Stem
Cell Technologies Inc, Vancouver, BC, Canada). The
probabilities of overall and event-free survival from
the time of transplantation were calculated according
to the Kaplan-Meier method [17]. The events consid-
ered for the event-free survival analysis were time
from the on-study date to relapse, evidence of disease
progression, or death from any cause. The date of the
ﬁrst event was used in calculating event-free survival.
Groups were compared by using the 2-sided log-rank
test [18,19]. Differences were considered signiﬁcant if
Table 2. Posttransplant Donor Cell Infusions, GVHD, NK Cell Alloreactvity of Donor versus Host, and Outcome
Unique
Patient
Number
Donor CD3 cells
per kilogram
day of infusion GVHD/Day of GVHD
NK Cell
Alloreactivity Cause of Death/Day of Death
Al 164 5  104/Day 27 — HLA-C Relapse/day 102
Al 167 5  104/Day 60 Acute, grade II/day 90 HLA-Bw4 —
Al 170 2.5  104/Day 58 Acute, grade III/Day 94 HLA-C —
4.5  104/Day 72
Al 172 2.5  104/Day 38 Acute, grade I/Day 65 HLA-A3 —
Al 176 1  104/Day 63 Acute, grade IV/Day III HLA-A3-Bw4 and -C —
Al 181 5  103/Day 95 — — Relapse/Day 116
5  104Day 111
Al 187 5  103/Day 72 Bronchiolitis obliterans (moderate)/Day 160 HLA-C Interstitial pneumonia/Day 223
Al 193 5  103/Day 59 Acute, grade II/Day 160 HLA-Bw4 —
Al 197 5  103/Day 37 Bronchiolitis obliterans (severe)/Day 58 — Invasive Candida infection/Day 646
Al 200 1  104/Day 70 — — CMV pneumonia/Day 96
Al 206 1  104/Day 25 — — Relapse/Day 186
Al 222 5  104/Day 38 HLA-C Relapse/Day 216
5  104/Day 107 Acute grade I/Day 120
5  104/Day 128
5  104/Day 133
1  105/Day 137
2  105/Day 141
4  105/Day 144
4  105/Day 151
4  105/Day 155
4  105/day 157
8  105/Day 158
8  105/Day 161
8  105/Day 163
1.6  106/Day 164 Acute, grade II (extensive skin alone)/Day 184
5  104/Day 188
1  105/Day 189
4  105/Day 191
6  105/Day 192
8  105/Day 196
8  105/Day 199
8  105/Day 210
Al 236 7  103/Day 31 Acute grade I/Day 113 — Relapse/Day 271
2  104/Day 83
Al 242 5  103/Day 90 Acute grade III/Day 111 HLA-C —
J. F. Lacerda et al.
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the P value was 
.05. Follow-up was updated to June
15, 2003.
RESULTS
Patients
A total of 14 patients (8 males and 6 females)
underwent transplantation (Table 1). Their median
age was 25 years (range, 13-45 years), and only 1
patient was younger than 18 years old. All the patients
had high-risk leukemia, and, according to the judg-
ment of the attending physicians, none had a signiﬁ-
cant chance for long-term survival without this ther-
apeutic approach. The median time from diagnosis to
transplantation was 12.5 months (range, 3-48
months). Of the 14 patients treated, 9 had chemore-
sistant blastic primary disease or relapse; 4 patients
had relapsed after a myeloablative autologous bone
marrow transplant. Five of the 9 patients with resis-
tant disease received low-dose intravenous cytarabine,
VP-16, or both in the 2 weeks before the conditioning
regimen for control of blast counts. Of the 5 patients
who received transplants in remission, only the patient
with acute biphenotypic leukemia was in ﬁrst com-
plete remission. One patient with AML was in second
complete remission, and the other 3 patients, also with
AML, were in third complete remission.
Stem Cell Mobilization, Collection, and Processing
No signiﬁcant adverse events occurred during
stem cell mobilization and collection. The patients
received a median of 5.4 106 (range, 2.9-13.8 106)
CD34 cells per kilogram, 1.62  104 (range, 0.33-
5.96  104) CD3 cells per kilogram, and 9.32  104
(range, 5.5-12.55  104) CD19 cells per kilogram.
These cell counts were obtained at the time of cryo-
preservation; FACS analysis was not performed after
thawing (the viability of the thawed cells by trypan
blue exclusion was 90% in all patients). With the
CD34 cell selection, a 4.5 to 5 log10 T-cell depletion
was achieved. T-cell depletion was the only prophy-
laxis for GVHD.
Engraftment and Toxicity of the Conditioning
Regimen
All 14 patients had primary and durable engraft-
ment after a median of 10 days of severe pancytopenia.
The median day of neutrophils 500/L and
1000/L was day 11 (range, day 9 to day 20) and day
12 (range, day 9 to day 22), respectively. Twelve of the
14 patients had a neutrophil count of 500/L between
days 9 and 12 after transplantation. The median day of
platelets 20 000/L and 50 000/L was day 19
(range, day 11 to never reached) and day 38 (range,
day 15 to never reached), respectively. Two patients
never had platelet recovery: 1 experienced early re-
lapse, and 1 died with CMV pneumonia. The latter
patient, who had late engraftment (neutrophils
500/L on day 20), developed interstitial pneumo-
nia on day 5 and was treated with intravenous ganci-
clovir and trimethoprim sulfamethoxazole. All but 1
patient had 100% donor cell engraftment conﬁrmed
by DNA chimerism studies between days 21 and 30
after transplantation. One patient with primary resis-
tant AML had 92% donor cells on day 21. He had a
full relapse shortly thereafter. On subsequent engraft-
ment analysis, all surviving patients were conﬁrmed to
have durable full donor engraftment. No late graft
rejections were observed.
The toxicity of the conditioning regimen was min-
imal; 1 patient died within the ﬁrst 100 days after
transplantation (the patient with accelerated chronic
myeloid leukemia who died of CMV pneumonia on
day 96). No instance of hepatic veno-occlusive disease
was observed.
Administration of Donor Leukocytes after
Transplantation and GVHD
All patients received at least 1 infusion of the
donor’s whole blood containing the number of CD3
cells speciﬁed in Table 2. Most patients received a
relatively low dose of donor T cells, which was esti-
mated to have a low potential of inducing GVHD. Of
the 11 evaluable patients, 8 developed acute GVHD (3
grade I, 2 grade II, 2 grade III, and 1 grade IV), and 2
patients developed chronic GVHD de novo (both
patients with bronchiolitis obliterans–organizing
pneumonia [BOOP]-like syndrome: 1 moderate and 1
severe). The median number of days between donor
leukocyte infusion and development of acute GVHD
was 30 days (range, 21-101 days). Five of the 8 patients
with acute GVHD had a complete resolution of this
syndrome with cyclosporin A plus steroids (n  1),
cyclosporine plus mycophenolate mofetil and steroids
(n  1), mycophenolate mofetil plus steroids (n  1),
or steroids alone (n  2). One patient who developed
grade III acute GVHD is still receiving mycopheno-
late mofetil and prednisolone 11 months after the
transplantation.
The 2 patients with clinical BOOP-like syndrome
developed this syndrome 21 and 88 days after donor
leukocyte infusion. One of these patients had a pro-
longed immunodeﬁciency and signiﬁcant pancytope-
nia requiring weekly platelet transfusions. He received
two boosts of puriﬁed CD34 from his donor (which
required 2 additional stimulations with G-CSF) with,
unfortunately, limited success. He never had circulat-
ing CD4 cells and died 20 months after transplanta-
tion with an invasive Candida species lung infection.
The second patient died with interstitial pneumonia,
possibly due to CMV. None of these patients had
developed acute GVHD.
One patient (Al 222) with primary resistant AML
Haploidentical Stem Cell Transplantation
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and a complex karyotype {45,XX, t(3;3)(q21;q26),
7[13]/45,XX, t(1;17)(p35;q12), t(3;3)(q21;q26),
7[2]}, who received a transplant from a full-haplo-
type mismatched donor, developed a mild skin rash on
day 120 after the infusion of limited doses of donor
leukocytes on days 38 and 107. Concomitantly with
relapse, she presented at 3 months with 1256  106/L
CD3, 559  106/L CD4, and 516  106/L
CD4CD45RA cells, which were the highest of the
group at this early time after transplantation. Al-
though the rash was suggestive of acute GVHD, it was
not treated and waned 2 days later. Subsequently, on
day 124, she presented with peripheral blood blasts,
and bone marrow relapse was conﬁrmed. This patient
had circulating myeloblasts for 3 months, with a bone
marrow inﬁltration that ranged between 2% and 50%
of total marrow cellularity. For this reason, she re-
ceived increasing doses of donor leukocytes (Table 2),
but developed extensive skin GVHD only after blast
reduction with a total dose of 25 mg of anti-CD33
monoclonal antibody conjugated with calicheamicin
(Mylotarg; Wyeth Ayerst, Collegeville, PA). The skin
GVHD was not treated, and the patient attained a
brief hematologic remission, but blast cells reappeared
immediately thereafter, and the patient died with in-
terstitial pneumonia. It is interesting to note that there
was a KIR ligand incompatibility in the graft-versus-
host direction in this case (donor HLA-Cw8 and pa-
tient HLA-Cw4), not controlling the leukemic clone.
Immunologic Reconstitution
All patients had a signiﬁcant impairment in the
reconstitution of peripheral blood lymphocyte sub-
sets. Typically, very few CD3 cells were detected in
the complete blood count before the administration of
donor leukocytes after transplantation and the devel-
opment of GVHD. As depicted in Figure 2, the me-
dian count of CD3 and CD4 cells was quite low
until more than 12 months after transplantation. The
emergence of naı¨ve CD4CD45RA cells was even
slower. Only 1 patient had more CD4 cells than
CD8 cells at 1 year after transplantation, and only 2
patients had more CD4 cells than CD8 cells at 2
years after transplantation. Higher levels of NK cells
were detected within the ﬁrst 3 months after trans-
plantation. Functional studies were not performed.
Posttransplantation Infections
Of the 14 patients, 7 had positive blood cultures
for gram-positive or gram-negative bacteria in the
ﬁrst month after transplantation. All of these episodes
were successfully treated. Four patients had Candida
albicans isolated; 2 of these cases had invasive infection
(1 esophageal and pulmonary and 1 pulmonary alone),
which ultimately contributed to their death. One of
these patients had primary resistant AML, and the
other had severe chronic GVHD.
The major infectious complication after trans-
plantation was due to CMV reactivation, which oc-
curred in 10 of the 14 cases. To treat this, most
patients received prolonged courses of intravenous
ganciclovir, foscarnet, and immunoglobulin in our
adult day hospital. CMV may have been a secondary
contributor to the death of 4 patients with AML who
relapsed after transplantation and was the cause of
death in 1 patient who developed interstitial pneumo-
nia on day 5 and in 1 of the patients with a BOOP-like
syndrome. Finally, 4 patients developed transitory
polyomavirus or adenovirus virurias.
Survival and Disease Relapse
As of June 15, 2003, 6 of 14 patients remain alive
with a median follow-up of 1331 days. All surviving
patients received a full 1-haplotype mismatched trans-
plant. Of the 14 patients who underwent transplanta-
tion, 9 had evidence of active leukemia before trans-
plantation. After the transplantation, all patients
attained remission, and only the ﬁrst patient (Al 164)
relapsed within 2 months. Of the 6 surviving patients,
4 were in remission at the time of transplantation. The
Kaplan-Meier estimate of the proportion of patients
alive (overall survival) and event free (event-free sur-
vival) at 4 years was, in both cases, 41.7%  13.5%
(Figure 3A and 3B).
All surviving patients developed acute GVHD,
and 5 of these 6 patients survive disease free more than
2 years after transplantation, with a Karnofsky score of
100, without chronic GVHD, and off treatment (1 of
these 5 patients had grade III and 1 had grade IV acute
GVHD; Table 2). None of the 4 patients without
GVHD was alive at 6 months after transplantation
(their median survival time was 109 days), whereas
58.3%  16.1% of the 10 patients who developed
GVHD are estimated to be alive at 4 years after
transplantation, with the median survival time not
reached (P 
 .0001).
We analyzed only NK cell alloreactivity of the
Figure 2. Median absolute number of CD3, CD4, CD8,
CD56, CD4CD45RA, and CD19 cells at the indicated timing
after transplantation. M indicates months.
J. F. Lacerda et al.
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donor against the recipient for the analysis of the
results. Following the observations of other groups, all
patients and donors were retyped for the HLA-C
locus [20,21]. Of the 14 donor-recipient pairs, 9 had
the following KIR ligand incompatibility in the graft-
versus-host direction: 5 pairs were mismatched at the
HLA-C locus, 2 pairs were mismatched for the HLA-
Bw4 group, 1 pair was mismatched at the HLA-A3
level, and 1 pair was mismatched for the HLA-A3,
-Bw4, and -C groups (Table 2). Six of these 9 patients
survive disease free. All of these 6 patients also devel-
oped GVHD after the infusion of donor cells after
transplantation. Of the 9 pairs with donor NK cell
alloreactivity against the patient, 66.7%  15.7% are
estimated to be alive at 4 years, with the median
survival time not reached, whereas the 5 patients with-
out NK cell alloreactivity all died with a median sur-
vival time of 186 days after transplantation. Three of
these 5 patients died in relapse. Two patients with NK
cell incompatibility in the direction of graft versus
host, both at the level of the HLA-C locus, also died
in relapse.
In 5 cases, death was due to leukemia relapse.
Three of these patients had primary resistant AML,
and the other 2 had chemotherapy-resistant relapse.
Two of these 5 patients had a period of complete
hematologic and cytogenetic remission that lasted 4 to
6 months. The relapse-related mortality for the whole
group at 4 years in all patients was 38.1% (Figure 4).
DISCUSSION
Most conditioning regimens in haplotype-dispar-
ate transplantations have included total body irradia-
tion, which is highly immunosuppressive, because of
the signiﬁcant risk of graft failure after the infusion of
T cell–depleted grafts [22]. Our conditioning regimen
was composed of chemotherapy alone. It used ATG,
ﬂudarabine, and thiotepa, administered at the same
doses as in the Perugia regimen [7,8]. To prevent
ATG infusion–related toxicity, we included pred-
nisolone 2 mg/kg/d on the days of ATG infusion (1
mg/kg before ATG and 1 mg/kg with ATG) [23].
Other groups have been reluctant to use steroids in
this setting because of apprehension with the devel-
opment of donor Epstein-Barr virus (EBV)–induced
B-cell lymphoproliferative disorders [7,8]. To replace
total body irradiation, we gave melphalan at a dose of
120 mg/m2 equally divided between days 4 and 3.
From our analysis of the literature, we believed that
this regimen, although fairly intensive and possibly
myeloablative, would have acceptable toxicity. In fact,
only 1 patient died within 100 days of transplantation,
and none developed hepatic veno-occlusive disease
(however, all patients received prophylaxis with pros-
taglandin E1).
We were also interested in investigating whether a
standard dose of puriﬁed CD34 cells would consis-
tently induce sustained engraftment in the setting of a
chemotherapy-alone conditioning regimen for hap-
loidentical transplantation. With the exception of 1
Figure 4. Relapse-related mortality for the entire group at 4 years
after transplantation was 38.1%.
Figure 3. The overall survival (A) and event-free survival (B) for the
entire group at 4 years after transplantation was 41.7%.
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patient, all the others received CD34 cells collected
in 2 standard-volume leukaphereses, which is a highly
feasible collection procedure. Because these cells were
selected immediately after the procedure, analyzed,
and cryopreserved, the number of cells infused to the
patient was likely lower than that recorded. We cryo-
preserved a median of 5.4  106 CD34 cells per
kilogram, which is approximately 50% of the number
of cells administered by the Perugia group and 25% of
the dose infused by the Tu¨bingen group [7,8,10].
With the CliniMacs system, a CD34 cell purity
higher than 97% was achieved, with minimal B- and
T-cell contamination. Although our patients were
conditioned with a chemotherapy-alone regimen,
consistent donor engraftment was conﬁrmed in all
patients by DNA analysis of hypervariable tandem
repeat regions, and no late graft failures occurred. In
the selection procedure, we incubated the leukaphere-
sed cells with human immunoglobulin to prevent non-
speciﬁc binding of the anti-CD34 monoclonal anti-
body to B cells, further decreasing the B-cell content
of the graft. This was a relevant issue, because we were
concerned that if the number of B cells in the graft
were higher, together with the profound immunosup-
pression of the conditioning regimen and the antici-
pated delayed immune recovery, the risk of donor
EBV-induced B-cell lymphoproliferative disorders af-
ter transplantation could be high [24,25]. None of
patients developed this complication, suggesting that
the number of donor EBV B cells in the graft was
very low. The patients were not monitored for EBV
replication in the posttransplantation period.
We also wanted to investigate whether the infu-
sion of a limited dose of donor leukocytes after trans-
plantation would hasten immune recovery and prevent
disease relapse. This was clearly a risky procedure, but
we hypothesized that the infusion of very low numbers
of donor T cells could probably be of beneﬁt without
a signiﬁcant risk of severe GVHD. Initially, our pro-
tocol was designed to infuse 2.5 to 5  104 donor
CD3 cells per kilogram between days 30 and 45 after
transplantation, but, with the development of GVHD
in the second, third, and fourth patients, this number
was decreased to 5 to 10  103 CD3 cells per kilo-
gram. After the infusion of donor cells after transplan-
tation, most patients developed GVHD. Because this
complication emerged early after transplantation, we
cannot distinguish the relative contribution of donor
T cells infused with the CD34 cells and those ad-
ministered after transplantation for the development
of GVHD. Typically, patients acquired peripheral
blood lymphocytes 1  109/L only after the devel-
opment of clinical GVHD. Even though we observed
a signiﬁcant increase in CD3 cells and their subsets
after the infusion of donor leukocytes, we cannot de-
termine whether this was beneﬁcial clinically, because
functional assays were not performed. Given the high
rate of GVHD, even with the posttransplantation in-
fusion of as little as 5  103 donor CD3 cells per
kilogram (which corresponds in most donors to 
0.3
mL of whole blood), it is unclear whether this strategy
should be pursued. Even though the 6 patients alive
developed GVHD, eventually suggesting a T cell–
mediated graft-versus-leukemia effect, we cannot de-
termine whether this was relevant for long-term dis-
ease control, because all of these donor-recipient pairs
also had a KIR ligand incompatibility in the direction
of graft versus host. It is of interest that 6 of 9 NK
cell–incompatible donor-recipient pairs developed
grade II to IV acute or chronic GVHD after the
posttransplantation infusion of donor leukocytes,
whereas only 1 of 5 pairs without NK-cell incompat-
ibility developed this complication.
The association of GVHD and NK cell alloreac-
tivity in haploidentical transplantation contrasts with
the study in mice by Ruggeri et al. [21], who observed
a protection against T cell–mediated GVHD in ani-
mals who underwent transplantation with haploiden-
tical grafts possessing NK cell alloreactvity against the
host, apparently because of donor NK cell lysis of host
antigen-presenting cells capable of initiating GVHD.
Also in contrast with these investigators [20,21], we
observed leukemia relapse in 2 patients with KIR
ligand incompatibility in the direction of graft versus
host, suggesting that other factors may also play a role
in the attainment of long-term disease-free survival in
patients with high-risk AML. In fact, both patients
had highly resistant leukemias with multiple cytoge-
netic abnormalities. Alternatively, it may also be im-
portant to transplant a higher CD34 cell dose than
we administered to induce a more potent NK cell
response against leukemia. Finally, it is unclear
whether patients with such refractory diseases should
be eligible for this type of transplantation, because the
risk of leukemia relapse is so high. As suggested by the
consensus recommendations reached at the Perugia
and Chicago meetings, protocols using haplotype-dis-
parate T cell–depleted grafts can be justiﬁed for pa-
tients in better condition with high-risk leukemia in
ﬁrst or second complete remission [26].
The signiﬁcant immunosuppression observed af-
ter transplantation was likely determined by the infu-
sion of a haplotype-disparate T cell–depleted graft.
The use of G-CSF after transplantation might also
have contributed to the delayed immune recovery,
because it has been shown to block interleukin-12
production by the antigen-presenting cells [27]. How-
ever, we were concerned that without G-CSF, en-
graftment might be compromised because of the num-
ber of CD34 cells transplanted [28]. We also
recognize that a higher number of CD34 cells may
be desirable because cells within the CD34 compart-
ment possess potent veto activity, neutralizing cyto-
toxic T-lymphocyte precursors and thereby facilitat-
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ing the induction of tolerance [29]. As reported by
other groups, NK cells emerged early after transplan-
tation in our patients [7,8,30]. In contrast, CD3 cells
and their subsets were quite low until 1 year after
transplantation. In the patients who developed acute
GVHD, a major increase in CD3, CD4, and CD8
cells expressing TCR / was noted, suggesting that
they were alloreactive. Both the Perugia and the Tu¨-
bingen groups reported faster emergence of these sub-
sets of cells after transplantation; this may be due to
the higher CD34 cell count infused and to their avoid-
ance of G-CSF [7,8,10,30].
The main infectious complication associated with
this prolonged immunosuppression was persistent
CMV reactivation. In most patients this was asymp-
tomatic, but it necessitated prolonged courses of in-
travenous ganciclovir, foscarnet, and immunoglobu-
lin. This infection clearly represents a major challenge
in the Portuguese population of patients submitted to
this type of transplantation because most adults are
CMV immunoglobulin G positive. Methods of adop-
tive immunotherapy with donor CMV-speciﬁc T-cell
clones would be highly valuable in this setting [31].
One patient developed interstitial pneumonia almost 2
years after transplantation, with full recovery after
intravenous ganciclovir, clarithromycin, and tri-
methoprim sulfamethoxazole. The etiology of this in-
fection is uncertain. He was always negative for CMV
during this episode. This event further demonstrates
that these patients remain severely immunocompro-
mised until late after transplantation.
With a projected overall and event-free survival of
41.7% at 4 years in a group of patients—13 adults and
1 child—with very high risk leukemia (9 of the 14
patients had primary or secondary resistant disease)
who received transplants from a full 1-haplotype mis-
matched donor in all but 1 case, we believe that these
results are encouraging and that the technique should
be further developed. In the future, patients with a
clear indication for an allogeneic stem cell trans-
plantation in earlier remission and who lack an
HLA-matched donor should probably be included in
programs of haplotype-disparate stem cell transplan-
tation.
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